Strategic area of application
Medical Technologies
Application market
Immune, AutoIm & Inflam. diseases - Neurological diseases - Oncology
Activities
Therapeutics, Pharma or Biotech
Technologies
Others
Presentation of company's activity
genOway is fully dedicated to the development of tailor-made transgenic mice, rats and cell lines, 380 academic institutions & 13 EU projects, 170 Life Sciences companies, and 17 of the Top 20 pharma companies.
Based on this success, genOway is proud to offer a variety of quality transgenesis services, and a complete range of innovative cutting-edge technology solutions to help add value and substance to your research program. This combination of expertise speeds up model development times and enhances the efficiency, security and relevance of the animal model ultimately developed.
Two Cost- and Time-saving solutions:
1) As a "One-stop" provider, genOways industrialized production facility guarantees the development of projects from A to Z (from the design to model validation/phenotyping)
2) In order to maximize the use of in vivo models, genOway has developed the concept of “2-in-1” models. Target validation (Knock-out), in vivo evaluation of compounds towards the human target (humanized mouse) and compound specificity studies can all be addressed within a single animal model.
Moreover, genOway develops animal models as ready-to-use tools aiming at increasing the predictability of in vivo pre-clinical analysis in many areas such as ADME-tox, Immunology, Neurology and Metabolic disorders. The use of these catalog models enables more relevant analysis of physiopathological studies compare to human physiology and increases the relevance of candidate molecules selection.
Key features of company
With twenty years’ experience working with the pharmaceutical industry, over the past few years genOway has decided to specialize in research models for immuno-oncology, which involves restimulating a patient’s immune system in order to combat the development of cancer cells. Immuno-oncology is now the No. 1 investment in pharmaceutical R&D, already representing over 35% of investment worldwide and over $25 billion among the top ten laboratories alone.
While continuing its core business of selling custom research models, genOway now has access to a market 20 times bigger through its catalog of research models. What’s the benefit? These models are immediately available and risk-free for researchers, as they have already been approved and published by leading pharmaceutical companies.
The company aims to build a comprehensive catalog of around 30 immuno-oncology research models by the end of 2021. The first third of the catalog has already been developed and approved by a consortium of leading immuno-oncology companies (AbbVie, AstraZeneca, BMS, Pfizer and Roche) and will soon hit the market. genOway also aims to replicate the catalog research model approach for other pathologies.
genOway plans to go even further over the long term thanks to a major innovative project to increase the success rate of clinical studies, in cooperation with the Gustave Roussy Institute in Villejuif (Paris) and the Léon Bérard Center in Lyon. In addition to its current preclinical studies market, this project will enable genOway to offer pharmaceutical companies innovative models for their clinical trials.
Recent news
Thanks to its new business model, genOway now has access to a market over 20 times the size of the company’s previous market in custom research models. By the end of 2021, genOway will be able to serve a global preclinical studies market worth over $2 billion, compared to just $100 million previously.
The company also expects to grow its profits significantly by the end of 2021. While each tailor-made model was developed for a single customer, catalog research models can now be offered to a broad range of pharmaceutical groups and biotechnology companies, essentially doubling genOway’s margin compared to its historical business model.
genOway therefore expects to see a rapid step-up in sales growth over the next 5 years, with an average annual growth between 25% and 35% from 2020 to 2024, thereby tripling revenues to over €30 million by 2024 and doubling the EBITDA margin to more than 25%.
Presentation of company's services
In addition to providing highly advanced technological solutions for transgenesis and model design, genOway offers interactive scientific consulting at every step as an essential part of the process. This premium consulting service allows genOway not just to better understand specific research needs and objectives but also to help enhance the reliability of in vivo studies.
genOway guarantees its customer access to a permanent, non-exclusive royalty-free license over patented technologies employed to create rodent or cellular models in order to use such a model for Research and Development purposes. The customer retains the ownership of the deliverables and can patent the model developed.
Presentation of company's technologies
genOway has an unparalleled portfolio of exclusive technologies that enables us to generate biologically relevant models while limiting the drawbacks of typical genetic modifications (e.g. embryonic or perinatal lethality, unregulated over expression of transgenes, genetic deregulation, non relevant physiological responses, etc.).
These technologies are thus able to provide scientists access to more refined genetically modified models.
- Homologous Recombination: Reference technology for humanized, Knockin and conditional Knockout models
- CRISPR/Cas9 Nuclease System: Reference technology for genetically modified rat and cellular models
- FLEx technology: Gold standard for the generation of kinase-dead mutations, inducible in a temporal and tissue-specific manner
- TET On/Off system: “On demand” gene induction
- Quick Knockin: Fast model development by transgene introduction into known permissive loci (e.g. HPRT, Rosa26)
- RMCE: Enables the swapping of large genomic regions, and recommended for the development of humanized models
